

OSCIENT PHARMACEUTICALS CORP  
Form 8-K  
May 03, 2004

---

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

## FORM 8-K

---

### CURRENT REPORT

Pursuant to Section 13 or 15(d) of  
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): May 3, 2004

---

# OSCIENT PHARMACEUTICALS CORPORATION

(Exact name of registrant as specified in its charter)

---

Massachusetts  
(State or other jurisdiction  
of incorporation)

0-10824  
(Commission  
File Number)

04-2297484  
(I.R.S. Employer  
Identification Number)

100 Beaver Street  
Waltham, Massachusetts 02453

(Address of principal executive offices, including zip code)

**(781) 398-2300**

**(Registrant's telephone number, including area code)**

---

Item 7. FINANCIAL STATEMENTS AND EXHIBITS.

(c) Exhibits

99.1 Press Release issued by Oscient Pharmaceuticals Corporation on May 3, 2004.

Item 9. REGULATION FD DISCLOSURE

On May 3, 2004, Oscient Pharmaceuticals Corporation issued a press release announcing its intention to issue convertible notes. A copy of the press release is attached hereto as Exhibit 99.1.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OSCIENT PHARMACEUTICALS CORPORATION

By:     /s/ Steven M. Rauscher    

Name: Steven M. Rauscher

Title: President and Chief Executive Officer

Date: May 3, 2004

EXHIBIT INDEX

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press Release issued by Oscient Pharmaceuticals Corporation on May 3, 2004.